GlassScriptPhysician profile
Josef Stehlik
NPI 1558458992
$211,835.37
in general payments reported to CMS, 2019-2025
19 companies · $55K in 2025
The $55K reported for 2025 was more than what 93% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,938 · 2021: $8,727 · 2022: $4,287 · 2023: $54K · 2024: $76K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $174K · Travel and Lodging: $8,491 · Food and Beverage: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $173,793.85 |
| Travel and Lodging | $8,490.60 |
| Food and Beverage | $2,258.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Transmedics, INC. | $143,202.31 | 2023-2025 | Organ Care System |
| Medtronic, INC. | $22,792.82 | 2021-2025 | Micra |
| Sanofi-Aventis U.S. LLC | $14,616.58 | 2021-2025 | |
| Novo Nordisk INC | $14,347.19 | 2024 | |
| Medtronic Vascular, INC. | $10,705.29 | 2019-2020 | |
| Abbott Laboratories | $3,731.73 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $1,204.92 | 2019-2022 | |
| One Lambda, INC. | $389.60 | 2019 | |
| Abiomed | $182.29 | 2023 | Impella |
| Alnylam Pharmaceuticals INC. | $164.84 | 2024 | Amvuttra |
| Cvrx, INC. | $142.27 | 2025 | Barostim Neo System |
| Paragonix Technologies, INC. | $138.03 | 2024 | Lungguard, Baroguard, Pancreaspak |
| Astrazeneca Pharmaceuticals LP | $127.50 | 2023 | Wainua |
| Alexion Pharmaceuticals, INC. | $90.00 | 2025 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josef Stehlik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.